---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Budget impact"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Budget impact. 1 evidence topic quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary/budget-impact"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Budget impact

<a id="heading-1.1.3"></a>

## 1.1.3 Budget Impact of Claseprubart

<a id="topic-1.1.3-1"></a>

### Summary

No price for claseprubart has been announced and no budget impact model of claseprubart has been published. A company presentation on the US CIDP market assumes an immunoglobulin price per patient of approximately $150,000 per year and an average biologic net price per patient of approximately $700,000 per year.

Published economic evidence concerns efgartigimod alfa injection and immunoglobulin. The Canadian CDA-AMC review estimated an incremental cost-effectiveness ratio for efgartigimod alfa injection of $1,872,111 per QALY gained compared with immunoglobulin, an annual cost of $1,030,527 per patient, and an incremental budget impact of approximately $691 million over the first 3 years. The second NICE draft guidance, open for consultation from 03 November 2026 to 23 November 2026, states that efgartigimod should not be used to treat progressive or relapsing active CIDP in adults after corticosteroids or immunoglobulins. In a US budget impact model for a hypothetical 25-million-member health plan with 708 immunoglobulin-treated patients, a 10% uptake of efgartigimod alfa in year 1 yielded a projected budget impact of $45,996,708, a 35.5% increase. A cost per responder analysis reported 12-month costs per responder of $256,792 for Panzyga 1 g/kg and $1,455,382 for Vyvgart Hytrulo.

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1); [CDA-AMC efgartigimod alfa reimbursement recommendation (2026)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/SR0894/2990?inline=1); [NICE ID6409 draft guidance (2026)](https://www.nice.org.uk/guidance/gid-ta11508/documents/draft-guidance-2); [NICE ID6409 project information (2026)](https://www.nice.org.uk/guidance/indevelopment/gid-ta11508); [Mallick et al. (2025)](https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-002929.html); [Muley et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42764727/)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
